OTCMKTS:ABSCF

AB Science News Headlines

$9.06
0.00 (0.00 %)
(As of 06/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.06
$9.06
50-Day Range
$8.65
$19.90
52-Week Range
$8.65
$26.70
Volume1 shs
Average Volume1,061 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

AB Science (OTCMKTS ABSCF) News Headlines Today

SourceHeadline
AB Science (OTCMKTS:ABSCF) Stock Price Down 13.5%AB Science (OTCMKTS:ABSCF) Stock Price Down 13.5%
americanbankingnews.com - June 11 at 12:10 AM
AB Science today announced that results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual MeetingAB Science today announced that results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting
finance.yahoo.com - June 10 at 2:24 PM
AB Science will host a live webcast on June 3, 2021 following the voluntary hold in the clinical studies of masitinibAB Science will host a live webcast on June 3, 2021 following the voluntary hold in the clinical studies of masitinib
finance.yahoo.com - June 2 at 10:12 AM
AB Science will host a live webcast on Tuesday May 25, 2021 on masitinib results in Prostate CancerAB Science will host a live webcast on Tuesday May 25, 2021 on masitinib results in Prostate Cancer
finance.yahoo.com - May 21 at 2:29 PM
AB Science today announced that results from masitinib study AB12005 in pancreatic cancer, have been selected for presentation at the upcoming ASCO Annual MeetingAB Science today announced that results from masitinib study AB12005 in pancreatic cancer, have been selected for presentation at the upcoming ASCO Annual Meeting
finance.yahoo.com - May 20 at 1:29 PM
AB Science reports today its annual financials as of 31 December 2020 and provides an update on its activitiesAB Science reports today its annual financials as of 31 December 2020 and provides an update on its activities
finance.yahoo.com - April 30 at 12:48 PM
AB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpointAB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint
finance.yahoo.com - April 29 at 3:57 PM
AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancerAB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer
finance.yahoo.com - March 31 at 1:35 PM
AB Sciences Masitinib: An Uncertain Success For Alzheimers DiseaseAB Science's Masitinib: An Uncertain Success For Alzheimer's Disease
seekingalpha.com - December 25 at 1:51 PM
AB Science announces the success of its capital raise for a total amount of 15 million eurosAB Science announces the success of its capital raise for a total amount of 15 million euros
finance.yahoo.com - December 21 at 8:58 AM
AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s diseaseAB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease
finance.yahoo.com - December 18 at 7:37 AM
AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020
finance.yahoo.com - December 17 at 8:19 AM
AB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s DiseaseAB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s Disease
finance.yahoo.com - December 16 at 2:17 PM
AB Science announces that Phase 2B/3 study evaluating oral in Alzheimer’s disease met its primary endpointAB Science announces that Phase 2B/3 study evaluating oral in Alzheimer’s disease met its primary endpoint
finance.yahoo.com - December 16 at 9:12 AM
AB Science will host a live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancerAB Science will host a live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancer
finance.yahoo.com - December 8 at 5:35 PM
AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary sharesAB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
finance.yahoo.com - October 29 at 4:18 AM
AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Largest Multiple Sclerosis Research ConferenceAB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Largest Multiple Sclerosis Research Conference
finance.yahoo.com - September 14 at 3:21 AM
AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International CongressAB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congress
finance.yahoo.com - September 8 at 7:22 AM
Biohaven, Casava, Shoinigi Taking Different Approaches to Alzheimer'sBiohaven, Casava, Shoinigi Taking Different Approaches to Alzheimer's
finance.yahoo.com - August 27 at 6:18 PM
Does AB Science S.A. (EPA:AB) Have A High Beta?Does AB Science S.A. (EPA:AB) Have A High Beta?
finance.yahoo.com - May 27 at 7:52 AM
AB Science (EPA:AB) Shareholders Booked A 86% Gain In The Last YearAB Science (EPA:AB) Shareholders Booked A 86% Gain In The Last Year
finance.yahoo.com - May 2 at 4:34 AM
Did Changing Sentiment Drive AB Science's (EPA:AB) Share Price Down A Worrying 62%?Did Changing Sentiment Drive AB Science's (EPA:AB) Share Price Down A Worrying 62%?
finance.yahoo.com - March 31 at 9:40 AM
How Should Investors Feel About AB Science S.A.'s (EPA:AB) CEO Pay?How Should Investors Feel About AB Science S.A.'s (EPA:AB) CEO Pay?
finance.yahoo.com - March 31 at 9:40 AM
This page was last updated on 6/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.